


DT05 Rec'd PCT/PTO 27 AUG 2002
PCF #10

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On August 29, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT

Attorney Docket No.: 080575-000000US
Client Ref. No.: P12975 DRB/GO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LINDHOFER and RUF

Application No.: 09/787,970

Filed: Not yet assigned

For: TIME-STAGGERED
UTILIZATION OF TUMOR CELLS IN
COMBINATION WITH INTACT
ANTIBODIES FOR IMMUNIZATION

Examiner: Not yet assigned

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed June 26, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.